Bristol Myers joins AstraZeneca in agreeing to drug price negotiation terms ahead of first deadline
Pharma companies are now reluctantly agreeing to participate in the Center for Medicare and Medicaid Services’ first round of negotiations for 10 drugs.
Ahead of a key Oct. 1 deadline, both Bristol Myers Squibb and AstraZeneca have now said they will participate in the negotiations with CMS, although nearly all of the companies on the initial list have insisted the negotiations are more akin to price controls.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.